Research in brief: Coagulopathy in COVID-19: Determining and managing thrombotic risk in COVID-19 infection

Clin Med (Lond). 2020 Jul;20(4):e59. doi: 10.7861/clinmed.rib.20.4.2.
No abstract available

MeSH terms

  • Anticoagulants / therapeutic use
  • Betacoronavirus*
  • Biomarkers / blood
  • Blood Coagulation Disorders / blood*
  • Blood Coagulation Disorders / virology
  • COVID-19
  • Case-Control Studies
  • Coronavirus Infections / blood
  • Coronavirus Infections / complications*
  • Fibrin Fibrinogen Degradation Products / metabolism*
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Pandemics
  • Partial Thromboplastin Time
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / complications*
  • Risk Factors
  • SARS-CoV-2
  • Thrombophilia / blood*
  • Thrombophilia / virology
  • Venous Thromboembolism / blood*
  • Venous Thromboembolism / drug therapy
  • Venous Thromboembolism / virology

Substances

  • Anticoagulants
  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • Heparin, Low-Molecular-Weight
  • fibrin fragment D